KEI was invited to participate in the “WHO Global Dialogue on Partnerships for Sustainable Financing of Noncommunicable Disease (NCD) Prevention and Control,” which was held in Copenhagen, Denmark, April 9-11, 2018. A web page for the event is here. Overall,… Continue Reading
On March 21, 2018, KEI asked the NIH to investigate the failure of James Griffin, the Dana-Farber Cancer Institute and Novartis to disclose millions of dollars in NIH grants related to two patents for the leukemia drug midostaurin, marketed by… Continue Reading
These were KEI comments to USTR regarding PhRMA’s efforts to target Malaysia as a Priority Foreign Country for issuing a compulsory license on sofosbuvir patents. Malaysia.14March2018.KEI.USTR.Special 301 March 14, 2018 The Honorable Robert Lighthizer United States Trade Representative Executive Office… Continue Reading
In the attached letter dated March 14, 2018 to Secretary of the Department of Health and Human Services (DHHS) Alex Azar, KEI is asking for an investigation into a failure to report NIH funding on US patent 7,964,580. This is… Continue Reading
On March 8, 2018, USTR and the interagency committee on the Special 301 held a hearing. KEI was one of the groups testifying. More on this process here: https://keionline.org/ustr/special301 I began our oral testimony discussing President Trump’s promise, during the… Continue Reading
USTR just sent out the schedule for the Special 301 hearing on March 8, 2018. 21 trade associations, civil society NGOs and academies will testify. Everyone is given 10 minutes, including questions, but persons testifying can provide additional materials to… Continue Reading
On Tuesday February 20, 2018, the U.S. Federal Trade Commission approved the Celgene acquisition of Juno, without requiring divestitures. The European Commission did not review the merger. KEI’s February 16, 2018 letter opposing the acquisition is available here. The following… Continue Reading
On February 14, 2018, KEI meet with the FTC to express our opposition to Celgene’s proposed acquisition of Juno Therapeutics. Celgene-Juno-KEI-FTC16Feb2018 The Celgene acquisition of Juno Therapeutics would give Celgene control over competing candidates for the treatment of multiple myeloma… Continue Reading
On February 9, 2018, the Trump Administration released a paper by the Counsel of Economic Advisers (CEA) on drug pricing. The paper on pricing was thought to have been led by economist Tomas Philipson, appointed to the CEA by President… Continue Reading
